CN103308670B - 用于预测对象患糖尿病和/或代谢综合征的风险的方法 - Google Patents

用于预测对象患糖尿病和/或代谢综合征的风险的方法 Download PDF

Info

Publication number
CN103308670B
CN103308670B CN201210509621.3A CN201210509621A CN103308670B CN 103308670 B CN103308670 B CN 103308670B CN 201210509621 A CN201210509621 A CN 201210509621A CN 103308670 B CN103308670 B CN 103308670B
Authority
CN
China
Prior art keywords
diabetes
risk
metabolic syndrome
predicting
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210509621.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103308670A (zh
Inventor
安德里斯·贝格曼
欧勒·米兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qirento Dx Co.,Ltd.
Original Assignee
Sphingotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec GmbH filed Critical Sphingotec GmbH
Publication of CN103308670A publication Critical patent/CN103308670A/zh
Application granted granted Critical
Publication of CN103308670B publication Critical patent/CN103308670B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201210509621.3A 2012-03-08 2012-10-08 用于预测对象患糖尿病和/或代谢综合征的风险的方法 Active CN103308670B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261608350P 2012-03-08 2012-03-08
EP12158680 2012-03-08
EP12158680.4 2012-03-08
US61/608,350 2012-03-08
EP12165062 2012-04-20
EP12165062.6 2012-04-20

Publications (2)

Publication Number Publication Date
CN103308670A CN103308670A (zh) 2013-09-18
CN103308670B true CN103308670B (zh) 2017-06-09

Family

ID=49115970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210509621.3A Active CN103308670B (zh) 2012-03-08 2012-10-08 用于预测对象患糖尿病和/或代谢综合征的风险的方法

Country Status (9)

Country Link
US (2) US10520512B2 (enExample)
EP (1) EP2823316B1 (enExample)
JP (1) JP6262669B2 (enExample)
CN (1) CN103308670B (enExample)
ES (1) ES2684512T3 (enExample)
IN (1) IN2014MN01937A (enExample)
RU (1) RU2685713C2 (enExample)
TR (1) TR201811201T4 (enExample)
WO (1) WO2013132090A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103308689B (zh) * 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
RU2745751C2 (ru) * 2015-02-27 2021-03-31 Сфинготек Гмбх Способ прогнозирования риска развития ожирения у субъекта
US10473670B2 (en) 2016-02-25 2019-11-12 University Of Kentucky Research Foundation Method of predicting obesity comprising measuring neurotensin
WO2022203533A1 (ru) * 2021-03-25 2022-09-29 Владимир Валерьевич ВОЛОБУЕВ Способ оценки предрасположенности к различным формам сахарного диабета 2го типа

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5430047A (en) * 1994-04-07 1995-07-04 Warner-Lambert Company Neurotensin antagonists
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US7271153B2 (en) * 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1793847A2 (en) 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
JP2008538812A (ja) * 2005-04-11 2008-11-06 アストラゼネカ アクチボラグ 方法
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
MX2011005963A (es) * 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
EP2374003B1 (en) 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
JP2013509588A (ja) * 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
UA58612U (uk) * 2010-06-04 2011-04-26 Высшее Государственное Учебное Заведение «Украинская Медицинская Стоматологическая Академия» Спосіб діагностики інсулінорезистентності у хворих на метаболічний синдром та цукровий діабет 2 типу
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
RU2745751C2 (ru) * 2015-02-27 2021-03-31 Сфинготек Гмбх Способ прогнозирования риска развития ожирения у субъекта

Also Published As

Publication number Publication date
JP2015512048A (ja) 2015-04-23
EP2823316B1 (en) 2018-05-23
RU2685713C2 (ru) 2019-04-23
JP6262669B2 (ja) 2018-01-17
US20150056203A1 (en) 2015-02-26
ES2684512T3 (es) 2018-10-03
CN103308670A (zh) 2013-09-18
US10520512B2 (en) 2019-12-31
EP2823316A1 (en) 2015-01-14
RU2014140427A (ru) 2016-04-27
IN2014MN01937A (enExample) 2015-07-10
TR201811201T4 (tr) 2018-09-21
US20200326350A1 (en) 2020-10-15
WO2013132090A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
US20200326350A1 (en) Method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject
CN103308673B (zh) 用于预测雌性对象中发生心血管事件的风险的方法
US20230147663A1 (en) Method for predicting the risk of getting cancer or diagnosing cancer in a female subject
US20210109102A1 (en) Method for predicting the risk of getting cancer or diagnosing cancer in a female subject
ES2879023T3 (es) Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular
CN107430135B (zh) 一种预测受试者的肥胖风险的方法
CN104937419B (zh) 预测受试者患癌症的风险或诊断癌症的方法
HK1189658B (en) A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome
HK1189658A (en) A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome
HK1189656B (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
HK1189656A (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
HK1189659A (en) A method for predicting the risk of getting a cardiovascular event in a female subject
HK1189659B (en) A method for predicting the risk of getting a cardiovascular event in a female subject
HK40009357A (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
HK1212762B (zh) 预测女性对象患癌症风险或诊断其癌症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189658

Country of ref document: HK

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1189658

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250506

Address after: Hohenzollern, Germany

Patentee after: Qirento Dx Co.,Ltd.

Country or region after: Germany

Address before: Eindorf, Germany

Patentee before: SPHINGOTEC GmbH

Country or region before: Germany